SASakine Akar

Sakine Akar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sakine Akar has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of a Benzimidazolium Salt on Colorectal Cancer Cells: Involvement of Apoptosis and Autophagy

    by Mustafa Cakir, Eda Acikgoz, Burak Kuzu, Sakine Akar, Halil Ozkol, Hamiyet Donmez-Altuntas, Senem Akkoc

    Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, necessitating the identification of novel small molecules capable of targeting multiple survival pathways. In this study, the antiproliferative potential of dds benzimidazole-palladium (Pd) complexes was evaluated across breast cancer (4T1, MDA-MB-231) and CRC (DLD-1, HT-29) cell lines using MTT assays. Following initial screening, CRC models were prioritized for mechanistic investigation due to the complexes’ superior cytotoxic profile, particularly that of the lead candidate 3a, which exhibited significant dose-dependent efficacy. Mechanistic analyses, employing immunofluorescence staining for LC3 and mTOR alongside Annexin V/PI flow cytometry, revealed that compound 3a triggers a potent dual response characterized by concomitant autophagy and apoptosis. Furthermore, functional assays indicated that 3a significantly impairs the metastatic hallmarks of CRC cells by inhibiting migration, cell adhesion, and colony formation. Gene expression profiling further elucidated that the anticancer efficacy of 3a is mediated by suppression of the AKT/mTOR/STAT3 signaling axis, thereby triggering an autophagic response that destabilizes cell adhesion and accelerates apoptosis. These molecular findings were corroborated by in silico molecular docking analyses, which demonstrated favorable binding affinities between compound 3a and key regulatory proteins, specifically BCL-2 and Caspase-3. Collectively, these results identify compound 3a as a promising multi-targeted anticancer agent that disrupts critical survival and metastatic pathways in CRC, warranting further preclinical and mechanistic exploration for therapeutic development.

  • Open Access

    Escin Attenuates Amyloid Beta 1‐42‐Induced Oxidative Stress, Apoptosis, and Neuroinflammation in Neuron‐Like SH‐SY5Y Cells

    by Sakine Akar, Ozge Alvur, Gulsah Evyapan, Berna Ozdem, Ilknur Porsuk Doru

    The pathogenesis of Alzheimer's disease (AD) involves amyloid beta (Aβ)‐induced oxidative stress, apoptotic cell death, and neuroinflammation, contributing to neuronal dysfunction. In our study, a differentiation protocol using retinoic acid was applied to SH‐SY5Y cells to generate a neuron‐like phenotype, and the neuroprotective efficacy of Escin was investigated by inducing Aβ1‐42‐mediated cytotoxicity. The experimental protocol involved an initial treatment with 2 µM Escin prior to Aβ1‐42 application. Cell viability, intracellular reactive oxygen species (ROS), apoptosis, and inflammatory mediator expression (NF‐κB, TNF‐α, IL‐1β) were assessed by MTT assay, flow cytometry with DCFH‐DA, flow cytometry with Annexin V‐FITC/7‐AAD staining, and RT‐qPCR, respectively. In our results, Aβ1‐42 exposure was found to significantly reduce cell viability and increase ROS production. Additionally, it was observed to enhance apoptotic cell death and increase pro‐inflammatory gene expression. Escin pretreatment was found to significantly mitigate these effects by reducing oxidative stress, apoptosis, and NF‐κB‐mediated inflammatory signaling. Furthermore, galantamine (10 µM), an approved AD treatment agent, was used as a positive control to compare the effects of Escin and confirmed the experimental model by exhibiting protective effects. In conclusion, these findings demonstrate that Escin is a promising neuroprotective agent and warrant further investigation into its potential to mitigate Aβ‐related neuronal damage in AD.


  • Open Access

    Anticancer Effects of a Benzimidazole Derivative in Colorectal Cancer Cells: Involvement of Autophagy and Apoptosis

    by Mustafa Çakır, Eda Açıkgöz, Sakine Akar, Halil Özkol, Hamiyet Altuntaş, Senem Akkoç

    Colorectal cancer(CRC) is among the leading causes of cancer-related deaths world-wide, but current chemotherapy strategies are insufficient, necessitating the identifica-tion of novel small molecules that can disrupt multiple survival pathways simultane-ously. In this study, the antiproliferative effects of benzimidazole-palladium complex compounds were evaluated in 4T1, MDA-MB-231, DLD-1, and HT-29 cancer cell lines using MTT assays. The autophagy and apoptosis-inducing capacities of the compounds, which showed significant cytotoxicity in CRC cells, were analyzed in detail using im-munofluorescence and flow cytometry methods. Furthermore, functional assays such as migration, adhesion, and colony formation were further investigated in CRC cells. The benzimidazole derivative drug candidate (3a) significantly reduced cell viability in HT-29 and DLD-1 cells. Mechanistic investigations using immunofluorescence and Annexin V/PI for LC3 and mTOR revealed that 3a triggered a dual response of au-tophagy and apoptosis. In CRC cells, compound 3a significantly impaired metastatic potential by inhibiting migration, colony formation, and cell adhesion. Gene expression analysis also showed that this compound suppressed the AKT/mTOR/STAT3 signaling axis, thereby triggering an autophagic response that compromised cell adhesion and accelerated apoptotic cell death. These findings suggest that compound 3a is a prom-ising anticancer candidate and warrants further mechanistic investigation.

  • The preventive effects of natural plant compound carvacrol against combined UVA and UVB-induced endoplasmic reticulum stress in skin damage of rats

    by Gulsah Evyapan, Halil Ozkol, Hatice Uce Ozkol, Özge Alvur, Sakine Akar

    The skin is constantly exposed to a variety of environmental stressors, including ultraviolet (UV) radiation. Exposure of the skin to UV radiation causes a number of detrimental biological damages such as endoplasmic reticulum (ER) stress. The ER stress response is a cytoprotective mechanism that maintains homeostasis of the ER by increasing the capacity of the ER against the accumulation of unfolded proteins in the ER. Carvacrol (CRV) is a monoterpenoid phenol found in essential oils with antimicrobial and anti-inflammatory activities. We investigated for the first time in the literature the potential protective role of CRV against combined UVA and UVB-induced skin damage by targeting the ER stress pathway in a rat model. For this purpose, expressions of Grp78, Perk, Atf6, Ire-1, Chop, Xbp1, Casp12, elF2α, and Traf2 genes related to ER stress were analyzed by RT-PCR and protein expression levels of GRP78, ATF6, CHOP, and XBP1 were determined by ELISA assay in tissue sections taken from the back of the rats. As a result of analysis, it was seen that the expression levels of aforementioned ER stress genes increased significantly in the UVA + UVB irradiated group compared to the control group, while their expression levels decreased markedly by supplementation of CRV in UVA + UVB + CRV group. With regard to expressions of foregoing proteins, their levels escalated notably with UVA + UVB application and decreased markedly by CRV supplementation. In conclusion, present study revealed that CRV ameliorates UVA + UVB-induced ER stress via reducing the expression of mRNA as well as proteins involved in the unfolded protein response (UPR) pathway and inducing apoptosis as evidenced from high Caspase12 level.


  • A benzimidazolium salt induces apoptosis and arrests cells at sub-G1 phase in epithelial ovarian cancer cells

    by Sakine Akar, Mustafa Cakir, Halil Ozkol, Senem Akkoc, Berna Ozdem

    Background Ovarian cancer, also known as a silent killer, is the deadliest gynecological cancer in women worldwide. Epithelial ovarian cancers constitute the majority of ovarian cancers, and diagnosis can be made in advanced stages, which greatly reduces the likelihood of treatment and lowers the survival rate. For the treatment of epithelial ovarian cancers, the search for synthetic agents as well as agents of natural origin continues. The effects of 1-(2-cyanobenzyl)-3-(4-vinylbenzyl)-1H-benzo[d]imidazole-3-ium chloride (BD), a benzimidazole derivative, were investigated on epithelial ovarian cancer cells. Methods and results In our study, the effects of BD on proliferation, colony formation, cell death by apoptosis and the cell cycle in A2780 and A2780 Adriamycin (ADR) ovarian cancer cell lines were investigated. Proliferation was examined with cell viability analysis, colony formation and apoptosis with Annexin V staining and cell cycle analyses with PI staining, respectively. As a result of the analyses, BD inhibited cell proliferation and colony formation, induced apoptosis and cell death at 48 h in A2780 and A2780 ADR cells at 10.10 and 10.36 µM concentrations, respectively. In addition, A2780 and A2780ADR cells were arrested in the Sub-G1 phase of the cell cycle. Conclusions BD suppresses cancer cell progression by showing antiproliferative effects on ovarian cancer cells. Further analyses are required to determine the mechanism of action of this agent and to demonstrate its potential as a suitable candidate for the treatment of epithelial ovarian cancer.


  • β-Escin reduces cancer progression in aggressive MDA-MB-231 cells by inhibiting glutamine metabolism through downregulation of c-myc oncogene

    by Sakine Akar, Hamiyet Donmez-Altuntas, Zuhal Hamurcu

    Background The c-myc oncogene, which causes glutamine dependence in triple negative breast cancers (TNBC), is also the target of one of the signaling pathways affected by β-Escin. Methods and results We sought to determine how c-myc protein affects glutamine metabolism and the proteins, glutamine transporter alanine-serine-cysteine 2 (ASCT2) and glutaminase (GLS1), in β-Escin-treated MDA-MB-231 cells using glutamine uptake and western blot analysis. Cell viability, colony formation, migration and apoptosis were also evaluated in MDA-MB-231 cells in response to β-Escin treatment using MTS, colony forming, wound healing, and Annexin-V assay. We determined that β-Escin decreased glutamine uptake and reduced c-myc and GLS1 protein expressions and increased the expression of ASCT2. In addition, this inhibition of glutamine metabolism decreased cell proliferation, colony formation and migration, and induced apoptosis. Conclusions In this study, it was suggested that β-Escin inhibits glutamine metabolism via c-myc in MDA-MB-231 cells, and it is thought that as a result of interrupting the energy supply in these cells via c-myc, it results in a decrease in the carcinogenic properties of the cells. Consequently, β-Escin may be promising as a therapeutic agent for glutamine-dependent cancers.


  • Open Access

    β-Escin Reduces Cancer Progression in TNBC by Inhibiting Glutamine Metabolism Through Downregulation of c-myc.

    by Sakine Akar, Hamiyet Altuntaş, Zuhal Hamurcu

    The oncogene c-myc, which causes glutamine dependence in TNBC, is also the target of one of the β-Escin affected signaling pathways. We sought to determine how c-myc protein affects glutamine metabolism and proteins ASCT2 and GLS1 in β-Escin-treated MDA-MB-231 cells by glutamine uptake and western blot analysis. We also evaluated cell viability, colony formation, migration and apoptosis in MDA-MB-231 cells in response to β-Escin treatment using MTS, colonoy forming, wound healing, and Annexin-V assay. We determined that β-Escin decreased glutamine uptake and decreased myc and GLS1 protein expressions, conversially increased the expression of ASCT2. In addition, we determined that this inhibition of glutamine metabolism decreases cell proliferation, colony formation and migration, and induces apoptosis. In this study, it has been revealed that β-Escin inhibits glutamine metabolism through c-myc in MDA-MB-231 cells, by causing a reduce in the carcinogenic properties of the cells as a result of interrupting the energy source of these cells. As a result, β-Escin can be used as a therapeutic agent in glutamine dependent cancers.

  • Open Access

    Pain management practices in the emergency departments in Turkey

    by Murat Cetin, Bora Kaya, Turgay Yilmaz Kilic, Nazife Didem Hanoğlu, Şervan Gökhan, Serkan Emre Eroğlu, Sakine Neval Akar, Ozgen Gonenc Cekic, Dicle Polat, Emre Üstsoy, et al.

    OBJECTIVES: This study aimed to evaluate pain management practices in the emergency departments (EDs) in Turkey and to evaluate the prevalence and etiologies of oligoanalgesia to identify possible improvement strategies. METHODS: This multicenter cross-sectional observational study was conducted in 10 tertiary care hospitals in Turkey. Patients who were admitted to the ED with pain chief complaints were included in the study. Both patients and physicians were surveyed with two separate forms by the research associates, respectively. The patient survey collected data about the pain and the interventions from the patients' perspective. The pain was evaluated using the Numerical Rating Scale. The physician survey collected data to assess the differences between study centers on pain management strategies and physician attitudes in pain management. RESULTS: Ten emergency physicians and 740 patients (male/female: 365/375) enrolled in the study. The median pain score at admission at both triage and ED was 7 (interquartile range: 5–8). The most frequent type of pain at admission was headache (n = 184, 24.7%). The most common analgesics ordered by physicians were nonsteroidal anti-inflammatory drugs (n = 505, 67.9%), and the most frequent route of administration was intramuscular injection (n = 396, 53.2%). About half of the patients (n = 366, 49.2%) received analgesics 10–30 min from ED admission. The posttreatment median pain score decreased to 3 (P < 0.001). About 79.2% of patients did not need a second analgesic administration (n = 589), and opioid analgesics were the most frequently administered analgesic if the second application was required. Physicians prescribed an analgesic at discharge from the ED in 55.6% of the patients (n = 414) and acute pain was present in 7.5% (n = 56) of the patients. CONCLUSION: Our study on the pain management practices in the EDs in Turkey suggested that high rate of intramuscular analgesic use and long emergency room stay durations are issues that should constitute the focus of our quality improvement efforts in pain management.